Moderna, Inc. (MRNA)
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna stock, which lost 27% of its value over two days, tumbled again Monday on a rare downgrade amid uncertainty for its vaccines.
Cathie Wood Bought This Stock After Its 27% Drop. Should You?
Famous investor Cathie Wood is known for scooping up great stocks when they're down. She focuses on the long-term picture rather than the company's near-term, temporary challenges.
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
On Thursday, Moderna Inc MRNA lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines.
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
COVID-19 vaccine maker Moderna, Inc. MRNA fell over 21% on Thursday after the company reduced its revenue guidance for the year, citing a highly competitive respiratory vaccine market in the U.S. and weak COVID-19 vaccine sales in Europe.
Moderna Q2: Focus On The Light At The End Of The Tunnel
Moderna investors suffered a 20% hammering yesterday as the market reacted to a downward guidance revision. However, Covid isn't expected to disappear. The market reset should help prime MRNA for a second-half recovery. Moderna's RSV vaccine could also help drive a re-rating in the second half.
Cathie Wood's Ark ETFs buy a bunch of Moderna stock after record selloff
High-profile investor Cathie Wood saw the record selloff in Moderna Inc.'s stock as an opportunity to bulk up her bets on the biotechnology company.
S&P 500 Gains and Losses Today: Moderna Drops as Soft Vaccine Demand Prompts Guidance Cut
Major U.S. equities indexes moved lower on the first day of August as a pair of reports elevated concerns about the trajectory of the U.S. economy.
Crude Oil Moves Lower; Moderna Shares Plunge
U.S. stocks traded lower toward the end of trading, with the Dow Jones index dipping more than 650 points on Thursday.
Stock Of The Day: Moderna Stock Plunges, Breaking Key Support Levels Following Earnings Report
Moderna, Inc. MRNA shares are getting hit because of a bad earnings report. The Street didn't like the numbers.
Moderna (MRNA) Q2 2024 Earnings Call Transcript
Moderna Inc. (NASDAQ:MRNA ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Stéphane Bancel - Chief Executive Officer Stephen Hoge - President Jamey Mock - Chief Financial Officer Lavina Talukdar - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Michael Yee - Jefferies Elliott Bosco - UBS Gena Wang - Barclays Luca Issi - RBC Capital Alexandria Hammond - Bank of America Edward Tenthoff - Piper Sandler Jessica Fye - JP Morgan Evan Wang - Guggenheim Greg - TD Securities Adi - Evercore ISI Operator Good day and thank you for standing by. Welcome to the Moderna second quarter 2024 conference call.
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.
Moderna shares dive on slashed 2024 sales forecast
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plummeted almost 20% after the vaccine maker slashed its full-year sales forecast for respiratory vaccines by up to $1 billion. It now expects product sales for its respiratory franchise, which includes COVID-19 and respiratory syncytial virus (RSV) vaccines, to be between $3 billion to $3.5 billion, compared to its earlier projection of $4 billion.
